References
- Lo Presti E, Dieli F, Fourniè JJ, et al. Deciphering human γδ T cell response in cancer: lessons from tumor-infiltrating γδ T cells. Immunol Rev. 2020;298(1):153–164. DOI:10.1111/imr.12904.
- Dieli F, Gebbia N, Poccia F, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood. 2003;102(6):2310–2311. DOI:10.1182/blood-2003-05-1655.
- Saura-Esteller J, de Jong M, King LA, et al. Gamma delta T-Cell based cancer immunotherapy: past-present-future. Frontiers in Immunology. 2022;13. DOI:10.3389/fimmu.2022.915837.
- Xu Y, Xiang Z, Alnaggar M, et al. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021;18(2):427–439. DOI:10.1038/s41423-020-0515-7.
- Almeida AR, Correia DV, Fernandes-Platzgummer A, et al. Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion/differentiation and preclinical proof of concept. Clin Cancer Res off J Am Assoc Cancer Res. 2016;22(23):5795–5804. DOI:10.1158/1078-0432.CCR-16-0597.
- Oberg HH, Peipp M, Kellner C, et al. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells. Cancer Res. 2014;74(5):1349–1360. DOI:10.1158/0008-5472.CAN-13-0675.
- Ganesan R, Chennupati V, Ramachandran B, et al. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia. Leukemia. 2021;35(8):2274–2284. DOI:10.1038/s41375-021-01122-7.
- van Diest E, Hernández López P, Meringa AD, et al. Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds. J Immunother Cancer. 2021;9(11):e003850. DOI:10.1136/jitc-2021-003850.
- Yang R, He Q, Zhou H, et al.Vγ2 x PD-L1, a bispecific antibody targeting both the Vγ2 TCR and PD-L1, improves the anti-tumor response of Vγ2Vδ2 T Cell. Frontiers in Immunology. 2022;13. DOI:10.3389/fimmu.2022.923969
- Rischer M, Pscherer S, Duwe S, et al. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol. 2004;126(4):583–592. DOI:10.1111/j.1365-2141.2004.05077.x.
- Rozenbaum M, Meir A, Aharony Y, et al. Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia. Frontiers in Immunology. 2020;11. DOI:10.3389/fimmu.2020.01347.
- Ang WX, Ng YY, Xiao L, et al. Electroporation of NKG2D RNA CAR improves Vγ9Vδ2 T cell responses against human solid tumor xenografts. Molecular Therapy - Oncolytics. 2020; 17: 421–430. DOI:10.1016/j.omto.2020.04.013.
- Nishimoto KP, Barca T, Azameera A, et al. Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models. Clin Transl Immunology. 2022;11(2):e1373. DOI:10.1002/cti2.1373.
- Makkouk A, Yang XC, Barca T, et al. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J Immunother Cancer. 2021;9(12):e003441. DOI:10.1136/jitc-2021-003441.
- Johanna I, Straetemans T, Heijhuurs S, et al. Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells. J Immunother Cancer. 2019;7(1):69. DOI:10.1186/s40425-019-0558-4.
- Wallet MA, Nishimura T, Del Casale C, et al. Induced pluripotent stem cell-derived gamma delta CAR-T cells for cancer immunotherapy. Blood. 2021;138(Supplement 1):2771. DOI:10.1016/j.soc.2019.02.005.